The global pharmaceutical landscape requires a delicate balance of high-volume production, stringent quality compliance, and accessible therapeutic solutions. Wings Biotech LLP has emerged as a premier force in this ecosystem by operating a highly wingsbiotechlifecare diversified business model. By structuring its operations into distinct, specialized divisions, the company efficiently bridges the gap between complex drug formulation and patient-centric delivery. Through its core pillars—Contract Manufacturing, Export, Institutional, and Metabolic divisions—Wings Biotech drives excellence across the global supply chain.

At the heart of the company’s infrastructure is its Contract Manufacturing division, operating out of a state-of-the-art facility in Baddi, Himachal Pradesh. Built in strict accordance with WHO-GMP standards, this facility functions as a centralized hub for top-tier third-party formulation services. The facility possesses the manufacturing versatility to seamlessly produce an exhaustive range of dosage forms under one roof, including:

• Solid oral dosages (tablets and capsules)
• Liquid oral formulations (syrups and suspensions)
• Topical preparations (ointments, creams, and lotions)
• Sterile injectables and specialized cosmetics

By acting as a reliable business-to-business (B2B) partner, Wings Biotech allows external brands to scale their market supply rapidly without sacrificing regulatory compliance.

The Export and Institutional divisions collectively ensure that the company’s vast therapeutic catalog reaches diverse patient populations worldwide. The Export division drives international growth by registering and distributing premium branded generics and over-the-counter (OTC) products across dynamic regions in Asia, Africa, and the Middle East. Rigorous Quality Assurance (QA) and Quality Control (QC) frameworks ensure every exported batch adheres to target country entry laws.

Domestically, the Institutional division focuses on public health equity by partnering with Indian government medical corporations. It consistently fulfills high-volume, bulk procurement contracts for critical healthcare bodies, including:

• Pharmaceuticals and Medical Devices Bureau of India (PMBI)
• Employees’ State Insurance Corporation (ESIC)
• Directorate General Armed Forces Medical Services (DGAFMS)

Recognizing the rising global burden of lifestyle diseases, Wings Biotech has dedicated substantial research and development resources to its Metabolic division. This specialized segment targets chronic conditions such as diabetes, thyroid malfunctions, and lipid disorders. By maintaining a deep portfolio of targeted oral hypoglycemic agents and metabolic regulators, the division provides clinicians with reliable long-term therapeutic options. This proactive therapeutic focus operates alongside the company’s established lines in dermatology and nutraceuticals, ensuring a comprehensive approach to modern wellness.